Menu
Search
|

Menu

Close
X

Acer Therapeutics Inc ACER.OQ (NASDAQ Stock Exchange Capital Market)

23.75 USD
-- (--)
As of Mar 20
chart
Previous Close 23.75
Open --
Volume --
3m Avg Volume 8,905
Today’s High --
Today’s Low --
52 Week High 34.10
52 Week Low 16.32
Shares Outstanding (mil) 10.09
Market Capitalization (mil) 239.57
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
EPS (USD)
FY18
-2.454
FY17
-2.303
FY16
-9.615
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
--
8.99
Price to Book (MRQ)
vs sector
5.31
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-63.13
12.11
Return on Equity (TTM)
vs sector
-63.13
13.22

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Gateway Center (300 Washingt
Suite 351
NEWTON   MA   02458

Phone:

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

SPONSORED STORIES